|
| (4-(4-bromo-3,5-bis(trifluoromethyl)phenylcarbamoyl)phenyl)difluoromethylphosphonic acid |
|
Mycobacterium |
Exoenzyme |
Preclinical (in vitro) |
Rawls KA, et al. 2009. Bioorg Med Chem Lett |
|
Compound 4g
(internal name in literature) |
|
Mycobacterium |
Biofilm |
Preclinical (in vitro) |
Zeiler MJ, et al. 2020. ChemMedChem |
|
M12
(internal name in literature) |
|
Mycobacterium |
Motility |
Preclinical (in vitro) |
Ouertatani-Sakouhi H, et al. 2017. PLoS One |
|
H44
(internal name in literature) |
|
Mycobacterium |
Motility |
Preclinical (in vitro) |
Ouertatani-Sakouhi H, et al. 2017. PLoS One |
|
| 5beta,6alpha-Bis[4-(4-methoxyphenyl)-1H-1,2,3-triazole-1-ylmethyl]-4,5,6,7-tetrahydro-1H-benzoimidazole-2-amine |
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Huigens RW 3rd, et al. 2009. Org Biomol Chem |
|
| 2-fluoro-N-(4-phenoxyphenyl)-N'-[4-(trifluoromethyl)phenyl]propanediamide |
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Singh VK, et al. 2022. Nat Commun |
|
| 3-(2-amino-1H-imidazol-5-yl)-N-(4-phenylbutyl)propanamide;hydrochloride |
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Ballard TE, et al. 2008. Chemistry |
|
| 3-(2-amino-1H-imidazol-5-yl)-N-[2-(4-bromophenyl)ethyl]propanamide;hydrochloride |
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Ballard TE, et al. 2008. Chemistry |
|
| 4-phenyl-1,4-dihydroindeno[1,2-d][1,3]thiazine-2,5-dione |
|
Pseudomonas |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Harmon DE, et al. 2010. Antimicrob Agents Chemother |
|
| N'-(3-chloro-4-cyanophenyl)-N-(4-cyanophenyl)propanediamide |
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Singh VK, et al. 2022. Nat Commun |
|
| | | |
